What does rescheduling to Schedule III mean for cannabis taxes?

Rescheduling cannabis to Schedule III would remove it from Section 280E's scope, allowing cannabis businesses to deduct ordinary business expenses for the first time. This could reduce effective federal tax rates from 60–80% to the 25–35% range typical of comparable businesses — a transformative financial change.

Will rescheduling make cannabis federally legal?

No. Schedule III substances are still controlled under federal law — they are regulated, not legal for general commerce. Cannabis would remain subject to DEA and FDA oversight. State-licensed cannabis operations would still be technically violating federal law, though enforcement risk is expected to decrease significantly.

When will cannabis rescheduling take effect?

As of 2026, the DEA's proposed rule has not been finalized. The timeline is uncertain and subject to public comment, administrative review, and potential litigation. Operators should monitor the rulemaking docket and not assume a specific effective date when making capital allocation decisions.

Cannabinoid Rescheduling Impact

What moving cannabis from Schedule I to Schedule III would mean for operators, banking, taxes, research, and state law — a practical analysis of the rescheduling proposal.

Where Things Stand

The Drug Enforcement Administration (DEA) issued a proposed rule to reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act, following an HHS recommendation in August 2023. A final rule has not yet been published as of 2026. The rulemaking record is substantial, and litigation challenging both the process and the merits is expected.

What Schedule III Would — and Would Not — Change

Tax Relief from 280E

Section 280E applies to Schedule I and II controlled substances. Reclassifying cannabis to Schedule III would remove it from 280E's scope, allowing cannabis businesses to deduct ordinary business expenses. This is the most immediate and economically significant impact.

Banking Access

Schedule III status would reduce — but not eliminate — banking risk for cannabis businesses. Banks remain subject to BSA/AML compliance obligations, and federal banking regulators would need to provide updated guidance. The SAFER Banking Act, if enacted, would provide more direct banking relief than rescheduling alone.

Research

Schedule III classification significantly reduces DEA regulatory barriers to cannabis research. Schedule I research requires DEA Schedule I researcher registration, a DEA-approved protocol, and supply from the DEA-licensed National Institute on Drug Abuse (NIDA). Schedule III research is subject to normal Schedule III controlled substance protocols — dramatically simpler.

FDA Jurisdiction

Rescheduling does not resolve the fundamental tension between federal drug law and state cannabis regulatory frameworks. The FDA's position that cannabis products approved as drugs (e.g., Epidiolex) cannot simultaneously be marketed as dietary supplements or food additives remains unchanged by rescheduling.

State Law Impact

Rescheduling has no automatic effect on state cannabis laws. States with current prohibitions remain prohibited; states with legalization frameworks retain those frameworks. Some state-specific drug schedules do automatically update when the federal CSA changes — operators should audit state scheduling implications.

Preparing for a Post-Rescheduling World

Operators should model business plans under both the current 280E regime and a post-rescheduling scenario, since the timing and scope of change remain uncertain.

Hoban Law Group's Position

Robert Hoban has advocated for federal cannabis reform across Congressional and executive channels for more than a decade. His practice is positioned to advise operators on the legal and strategic implications of rescheduling when it occurs.

[Discuss rescheduling strategy](/consultation?source=insights&topic=cannabinoid-rescheduling-impact&matter_type=regulatory_compliance) with Hoban Law Group.